Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation
Goldenrod Therapeutics, Inc., an innovator in brain inflammation treatments for multiple neurological conditions, today announced that it has completed the initial closing under its $6.5 million Series Seed preferred stock round, led by Ataxia Ventures and an affiliate of Fannin Partners.
